Anglo American to pay for AIDS drugs
Anglo American says it will pay for antiretroviral drugs for employees suffering from HIV/AIDS.The program could cost as much as R16.8 million (US$1.6 million) in the first year. In addition to extend…
Anglo American says it will pay for antiretroviral drugs for employees suffering from HIV/AIDS.The program could cost as much as R16.8 million (US$1.6 million) in the first year. In addition to extend…
Toronto stocks managed to close out the week with modest gains despite a 2% decline in the gold subindex. The S&P/T…
Placer Dome (PDG-T), now with more than 31% of AurionGold’s shares, has yet again extended its unconditional final…
Buoyed by a higher gold price and the sale of its residual interest in the Casa Berardi mine in northwestern Que.,…
Montreal-based Alcan (AL-T) has doubled to 40% its stake in the 243,000-tonne, low-cost Aluminerie Alouette aluminu…
Vancouver –The initial results from an on going $3.9 million program on the Meadowbank property in Nunavut continu…
Higher production in the second quarter translated into more revenue for North American Palladium (PDL-T), but earn…
Vancouver — Western Copper Holdings (WTC-T) has resumed drilling at its 100% owned Penasquito silver-gold-lead-zin…
Vancouver — Rubicon Minerals (RMX-V) is gearing up to commence a drill program on its Golden Promise project in Ne…
Muskox Minerals (MSK-V) has renewed drilling at the Muskox intrusion in Nunavut. This time, the holes are aimed at…
The golds gained 8.31 points or 5% to make 174.45 points and led Toronto stocks to a slightly higher end on Thursda…
Drilling by Aurizon Mines (ARZ-T) at the Casa Berardi property in northwestern Quebec has intersected a new zone of…
By continuing to browse you agree to our use of cookies. To learn more, click more information
Dear user, please be aware that we use cookies to help users navigate our website content and to help us understand how we can improve the user experience. If you have ideas for how we can improve our services, we’d love to hear from you. Click here to email us. By continuing to browse you agree to our use of cookies. Please see our Privacy & Cookie Usage Policy to learn more.